TrimRX
US$ 23.79
global glp-1 obesity drug market size forecast 2030 to Hit USD 66.57 Billion by 2035 Anti-Obesity Drugs Market Size &
Description
It contributes to a variety of disorders, including type 2 diabetes, cardiovascular disease, hypertension, stroke, and cancer
The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time
Conclusion GLP-1 microdosing sits between biological plausibility and clinical uncertainty
doi: 10.1016/j.tem.2020.02.006 [DOI] [PubMed] [Google Scholar] 133
These additional multiple-dose cohorts were not included in the current dataset
Contrariwise, in the study by Jensterle et al
